HRP20030726B1 - Atorvastatin kalcij u farmaceutskom obliku, njegova kompozicija i farmaceutska formulacija koja obuhvaä†a atorvastatin kalcij - Google Patents

Atorvastatin kalcij u farmaceutskom obliku, njegova kompozicija i farmaceutska formulacija koja obuhvaä†a atorvastatin kalcij

Info

Publication number
HRP20030726B1
HRP20030726B1 HRP20030726AA HRP20030726A HRP20030726B1 HR P20030726 B1 HRP20030726 B1 HR P20030726B1 HR P20030726A A HRP20030726A A HR P20030726AA HR P20030726 A HRP20030726 A HR P20030726A HR P20030726 B1 HRP20030726 B1 HR P20030726B1
Authority
HR
Croatia
Prior art keywords
atorvastatin
atorvastatin calcium
calcium
pharmaceutical
amorphous
Prior art date
Application number
HRP20030726AA
Other languages
English (en)
Croatian (hr)
Inventor
Janez Kerc
Salobir Mateja
Sasa Bavec
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030726(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of HRP20030726A2 publication Critical patent/HRP20030726A2/hr
Publication of HRP20030726B1 publication Critical patent/HRP20030726B1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20030726AA 2001-03-14 2002-03-13 Atorvastatin kalcij u farmaceutskom obliku, njegova kompozicija i farmaceutska formulacija koja obuhvaä†a atorvastatin kalcij HRP20030726B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100069A SI20848A (sl) 2001-03-14 2001-03-14 Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
PCT/IB2002/000736 WO2002072073A2 (en) 2001-03-14 2002-03-13 Pharmaceutical formulation comprising atorvastatin calcium

Publications (2)

Publication Number Publication Date
HRP20030726A2 HRP20030726A2 (en) 2005-04-30
HRP20030726B1 true HRP20030726B1 (hr) 2013-04-30

Family

ID=20432850

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20030726AA HRP20030726B1 (hr) 2001-03-14 2002-03-13 Atorvastatin kalcij u farmaceutskom obliku, njegova kompozicija i farmaceutska formulacija koja obuhvaä†a atorvastatin kalcij

Country Status (25)

Country Link
US (1) US7030151B2 (enExample)
EP (2) EP2263655B1 (enExample)
JP (1) JP4295988B2 (enExample)
KR (1) KR100905730B1 (enExample)
CN (1) CN1630510B (enExample)
AT (1) ATE500818T1 (enExample)
BG (1) BG66339B1 (enExample)
BR (1) BR0207880A (enExample)
CA (1) CA2440331C (enExample)
CZ (1) CZ306128B6 (enExample)
DE (1) DE60239425D1 (enExample)
ES (2) ES2417881T3 (enExample)
HR (1) HRP20030726B1 (enExample)
HU (1) HU230213B1 (enExample)
IL (2) IL157534A0 (enExample)
ME (1) ME00517B (enExample)
MX (1) MXPA03008340A (enExample)
PL (2) PL217835B1 (enExample)
RS (2) RS55021B1 (enExample)
RU (1) RU2293555C2 (enExample)
SI (2) SI20848A (enExample)
SK (1) SK287925B6 (enExample)
UA (1) UA78201C2 (enExample)
WO (1) WO2002072073A2 (enExample)
ZA (1) ZA200306575B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
IL152179A (en) 2000-04-10 2009-06-15 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622697A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
AP1571A (en) 2001-06-29 2006-02-10 Warner Lambert Co Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
AU2003245736A1 (en) * 2002-02-14 2003-09-04 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
TR200301614A2 (tr) * 2003-09-26 2005-10-21 Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş. Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
EP2540704B1 (en) 2004-05-05 2019-07-03 Pfizer Products Inc. Benethamine salt forms of atorvastatin
US8026376B2 (en) 2004-07-20 2011-09-27 Pfizer, Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)
JP2008517992A (ja) 2004-10-28 2008-05-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アモルファスのアトルバスタチンを形成する方法
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
ES2263370B1 (es) * 2005-02-16 2007-12-01 Ercros Industrial, S.A. Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion.
WO2006123358A2 (en) * 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Stabilized atorvastatin-containing formulation
JP5002904B2 (ja) * 2005-04-04 2012-08-15 ブラザー工業株式会社 無線タグ通信装置、その通信方法、及びその通信プログラム
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
EP1923057A1 (en) * 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US7772273B2 (en) * 2006-02-10 2010-08-10 Lifecycle Pharma A/S Stabilized atorvastatin
US20080038332A1 (en) * 2006-08-10 2008-02-14 Cai Gu Huang Stable pharmaceutical formulation comprising atorvastatin calcium
EP2098235B1 (en) * 2006-12-01 2013-08-21 Nitto Denko Corporation Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
TW200838479A (en) * 2006-12-01 2008-10-01 Nitto Denko Corp Percutaneously absorbable preparation
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
WO2009145269A1 (ja) * 2008-05-30 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 経皮吸収製剤
WO2009145177A1 (ja) * 2008-05-30 2009-12-03 日東電工株式会社 ドネペジル含有貼付製剤およびその包装体
US20100151034A1 (en) * 2008-09-30 2010-06-17 Astellas Pharma Inc. Granular pharmaceutical composition of atorvastatin for oral administration
MY159533A (en) * 2009-01-02 2017-01-13 Univ Putra Malaysia Porous bioceramic composition for bone repair
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
RU2404767C1 (ru) * 2009-08-11 2010-11-27 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
JP6360881B2 (ja) 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
CN103705484B (zh) * 2014-01-03 2015-05-20 华北制药集团新药研究开发有限责任公司 一种稳定的阿托伐他汀钙片及其制备方法
CN104013617A (zh) * 2014-05-13 2014-09-03 万特制药(海南)有限公司 一种含有依折麦布和阿托伐他汀钙的组合物及其制备方法
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
CN110339365A (zh) * 2018-04-02 2019-10-18 强生化学制药厂股份有限公司 一种可提高口服他汀类药物生体可用率的医药组合物及其用途
CN109044989A (zh) * 2018-10-09 2018-12-21 河南师范大学 一种阿托伐他汀钙胶囊制剂及其制备方法
KR102643099B1 (ko) 2020-01-31 2024-03-05 주식회사 일원바이오 양춘사 및 백출 복합 추출물을 유효성분으로 함유하는 고지혈증 또는 동맥경화의 예방, 개선 또는 치료용 조성물
KR20210098059A (ko) 2020-01-31 2021-08-10 주식회사 일원바이오 양춘사 추출물을 유효성분으로 함유하는 고지혈증 또는 동맥경화의 예방, 개선 또는 치료용 조성물
WO2021237143A1 (en) * 2020-05-22 2021-11-25 Durect Corporation Treatment of non-alcoholic steatohepatitis (nash)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1997003960A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)
WO1997003958A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2000035424A1 (en) * 1998-12-16 2000-06-22 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
WO2001076566A1 (en) * 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
FR2700452B1 (fr) 1993-01-20 1995-03-24 Mgb Structure transformable de réception du corps d'une personne, par exemple siège-berceau pour enfant.
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
DE60008608T2 (de) * 2000-06-09 2004-12-30 Lek Pharmaceutical And Chemical Co. D.D. Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
US6806290B2 (en) * 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO1997003960A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)
WO1997003958A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
WO2000035424A1 (en) * 1998-12-16 2000-06-22 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
WO2001076566A1 (en) * 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids

Also Published As

Publication number Publication date
HRP20030726A2 (en) 2005-04-30
HU230213B1 (hu) 2015-10-28
DE60239425D1 (de) 2011-04-21
JP2004533999A (ja) 2004-11-11
YU69603A (sh) 2006-05-25
PL217835B1 (pl) 2014-08-29
ES2361609T3 (es) 2011-06-20
ATE500818T1 (de) 2011-03-15
KR20040025901A (ko) 2004-03-26
RS20110313A (sr) 2011-10-31
CA2440331A1 (en) 2002-09-19
SI1499297T1 (sl) 2011-07-29
CZ20032469A3 (cs) 2004-09-15
SK287925B6 (sk) 2012-04-03
BR0207880A (pt) 2004-03-02
PL371919A1 (en) 2005-07-11
EP1499297B1 (en) 2011-03-09
RS51746B (sr) 2011-10-31
ZA200306575B (en) 2004-09-30
WO2002072073A2 (en) 2002-09-19
CN1630510B (zh) 2012-04-04
KR100905730B1 (ko) 2009-07-01
BG108175A (en) 2004-09-30
US20040138290A1 (en) 2004-07-15
RU2003130378A (ru) 2005-04-10
ME00517B (me) 2011-10-10
EP1499297A2 (en) 2005-01-26
PL211803B1 (pl) 2012-06-29
BG66339B1 (bg) 2013-07-31
SI20848A (sl) 2002-10-31
WO2002072073A3 (en) 2004-05-13
RU2293555C2 (ru) 2007-02-20
EP2263655B1 (en) 2013-04-24
UA78201C2 (en) 2007-03-15
IL157534A0 (en) 2004-03-28
IL157534A (en) 2009-12-24
CN1630510A (zh) 2005-06-22
JP4295988B2 (ja) 2009-07-15
CZ306128B6 (cs) 2016-08-17
HUP0303434A3 (en) 2011-09-28
CA2440331C (en) 2008-05-06
EP2263655A1 (en) 2010-12-22
PL396343A1 (pl) 2012-01-16
RS55021B1 (sr) 2016-11-30
SK11362003A3 (sk) 2004-02-03
ES2417881T3 (es) 2013-08-09
US7030151B2 (en) 2006-04-18
MXPA03008340A (es) 2004-10-15
HUP0303434A2 (hu) 2004-01-28

Similar Documents

Publication Publication Date Title
HRP20030726B1 (hr) Atorvastatin kalcij u farmaceutskom obliku, njegova kompozicija i farmaceutska formulacija koja obuhvaä†a atorvastatin kalcij
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
TWI454265B (zh) 含有羅蘇伐他汀鈣（ｒｏｓｕｖａｓｔａｔｉｎ ｃａｌｃｉｕｍ）之藥學組成物
NO20035675D0 (no) Krystallinske former av (R-(R*,R*))-2-(4-fluorfenyl)- <beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) (Atorvastatin)
IL160795A0 (en) Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
CA2251886A1 (en) An oral pharmaceutical formulation containing ibandronate
WO2006134604A1 (en) Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
IL179718A0 (en) Pharmaceutical composition containing irbesartan
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
CA2488422A1 (en) Stable solid medicinal ramosetron composition for oral administration
KR101283147B1 (ko) 로수바스타틴 칼슘의 약학적 조성물
EP2575757A1 (en) Water soluble formulation comprising a combination of amlodipine and a statin
WO2005053660A3 (en) Pharmaceutical compositions comprising danazol
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
CA2373962A1 (en) Immediate release medicinal compositions for oral use
CA2612769A1 (en) Improved pharmaceutical composition containing hmg-coa reductase inhibitor and method for the preparation thereof
WO2005030183A2 (en) A method for the preparation of atorvastatin calcium tablets
WO2003097039A1 (en) Stable dosage forms comprising atorvastatin calcium
JP2003095939A (ja) 安定なプラバスタチンナトリウム錠
UA93202C2 (ru) Полиморфная форма кристаллической гемикальциевой соли аторвастатина

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190228

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200225

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210225

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220313